Pharmacotherapy for obesity: Novel agents and paradigms

Therapeutic Advances in Chronic Disease

Volumn 5, Issue 3, 2014, Pages 135-148

  Manning, Sean ^a   Pucci, Andrea ^a   Finer, Nicholas ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Appetite suppressant; Liraglutide; Lorcaserin; Obesity; Pharmacotherapy; Phentermine; Topiramate; Weight loss

Indexed keywords

2, 4 DINITROPHENOL; AMFEBUTAMONE PLUS NALTREXONE; AMFEPRAMONE; AMINOREX; AMPHETAMINE DERIVATIVE; ANTIOBESITY AGENT; BELORANIB; DEXFENFLURAMINE; FENFLURAMINE; LIRAGLUTIDE; LORCASERIN; METFORMIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PHENYLPROPANOLAMINE; PLACEBO; RIMONABANT; RM 493; SIBUTRAMINE; SULFONYLUREA; UNCLASSIFIED DRUG;

APPETITE; BLOOD PRESSURE; BODY MASS; CHEMOTHERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EXERCISE; HUMAN; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 84898987526     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622314522848     Document Type: Review

References (70)

1. Allison D. Gadde K. Garvey W. Peterson C. Schwiers M. Najarian T. et al. (2012) Controlled-release phentermine / topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20: 330–342.
2. Anderson J. Konz E. Frederich R. Wood C. (2001) Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 74: 579–584.
3. Arterburn D. Westbrook E. Terrell A. (2013) Weight control practices of severely obese patients who are not seeking bariatric surgery. Obesity (Silver Spring) 21: 1509-1513.
4. Astrup A. Carraro R. Finer N. Harper A. Kunesova M. Lean M. et al. (2012) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 36: 843–854.
5. Astrup A. Caterson I. Zelissen P. Guy-Grand B. Carruba M. Levy B. et al. (2004 b) Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 12: 1658–1669.
6. Astrup A. Rossner S. Finer N. van Gaal L. (2013) Obesity in Europe – does anybody care? Expert Opin Pharmacother 14: 971–973.
7. Astrup A. Rossner S. van Gaal L. Rissanen A. Niskanen L. Al Hakim M. et al. (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374: 1606–1616.
8. Astrup A. Toubro S. (2004 a) Topiramate: a new potential pharmacological treatment for obesity. Obes Res 12(Suppl.): 167S-173S.
9. Berndt S. Gustafsson S. Magi R. Ganna A. Wheeler E. Feitosa M. et al. (2013) Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet 45: 501-512.
10. Bray G. (2013) Why do we need drugs to treat the patient with obesity? Obesity (Silver Spring) 21: 893–899.
11. Brownell K. (2000) The Learn Program for Weight Management. Euless, TX: Amer Health Pub Co.
12. Butler P. Elashoff M. Elashoff R. Gale E. (2013) A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 36: 2118–2125.
13. Caterson I. Finer N. Coutinho W. van Gaal L. Maggioni A. Torp-Pedersen C. et al. (2012) Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Diabetes Obes Metab 14: 523–530.
14. Chan E. He Y. Chui C. Wong A. Lau W. Wong I. (2013) Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev 14: 383–392.
15. Cohen D. (2013) Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 346: f3680.
16. Dunkley A. Charles K. Gray L. Camosso-Stefinovic J. Davies M. Khunti K. (2012) Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta-analysis. Diabetes Obes Metab 14: 616–625.
17. El-Sayed Moustafa J. Froguel P. (2013) From obesity genetics to the future of personalized obesity therapy. Nat Rev Endocrinol 9: 402–413.
18. Fabricatore A. Wadden T. Womble L. Sarwer D. Berkowitz R. Foster G. et al. (2007) The role of patients’ expectations and goals in the behavioral and pharmacological treatment of obesity. Int J Obes (Lond) 31: 1739–1745.
19. Fidler M. Sanchez M. Raether B. Weissman N. Smith S. Shanahan W. et al. (2011) A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 96: 3067–3077.
20. Finer N. (2001) Low-calorie diets and sustained weight loss. Obes Res 9(Suppl. 4): 290S-294S.
21. Finer N. Finer S. Naoumova R. (1992) Drug therapy after very-low-calorie diets. Am J Clin Nutr 56: 195S-198S.
22. Finucane M. Stevens G. Cowan M. Danaei G. Lin J. Paciorek C. et al. (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377: 557–567.
23. Fiorella D. Helsley S. Lorrain D. Rabin R. Winter J. (1995) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. III: The mechanistic basis for supersensitivity to the LSD Stimulus following serotonin depletion. Psychopharmacology (Berl) 121: 364–372.
24. Flegal K. Carroll M. Kit B. Ogden C. (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307: 491–497.
25. Foster G. Wadden T. Vogt R. Brewer G. (1997) What is a reasonable weight loss? Patients’ expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 65: 79–85.
26. Gadde K. Allison D. Ryan D. Peterson C. Troupin B. Schwiers M. et al. (2011) Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (conquer): a randomised, placebo-controlled, phase 3 trial. Lancet 377: 1341–1352.
27. Garvey W. Ryan D. Look M. Gadde K. Allison D. Peterson C. et al. (2012) Two-year sustained weight loss and metabolic benefits with controlled-release phentermine / topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 95: 297–308.
28. Grieve E. Fenwick E. Yang H. Lean M. (2013) The disproportionate economic burden associated with severe and complicated obesity: a systematic review. Obes Rev 14: 883-894.
29. Hemo B. Endevelt R. Porath A. Stampfer M. Shai I. (2011) Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals. Diabetes Res Clin Pract 94: 269–275.
30. Holst J. (2013) Incretin hormones and the satiation signal. Int J Obes (Lond) 37: 1161-1168.
31. Horowitz M. Flint A. Jones K. Hindsberger C. Rasmussen M. Kapitza C. et al. (2012) Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 97: 258–266.
32. Hutter M. Schirmer B. Jones D. Ko C. Cohen M. Merkow R. et al. (2011) First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg 254: 410–420; discussion 420–422.
33. James W. Caterson I. Coutinho W. Finer N. van Gaal L. Maggioni A. et al. (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363: 905–917.
34. Karmali S. Brar B. Shi X. Sharma A. de Gara C. Birch D. (2013) Weight recidivism post-bariatric surgery: a systematic review. Obes Surg 23: 1922-1933
35. Kashyap S. Bhatt D. Wolski K. Watanabe R. Abdul-Ghani M. Abood B. et al. (2013) Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 36: 2175–2182.
36. Kim S. Abbasi F. Lamendola C. Liu A. Ariel D. Schaaf P. et al. (2013) Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care 36: 3276-3282.
37. Lean M. Brosnahan N. McLoone P. McCombie L. Higgs A. Ross H. et al. (2013 a) Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity. Br J Gen Pract 63: e115–e124.
38. Lean M. Carraro R. Finer N. Hartvig H. Lindegaard M. Rossner S. et al. (2013 b) Tolerability of nausea and vomiting, and associations with weight loss, in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond) 14 August (epub ahead of print).
39. Loveman E. Frampton G. Shepherd J. Picot J. Cooper K. Bryant J. et al. (2011) The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol Assess 15: 1–182.
40. Lovshin J. Drucker D. (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5: 262–269.
41. Magi R. Manning S. Yousseif A. Pucci A. Santini F. Karra E. et al. (2013) Contribution of 32 GWAS-identified common variants to severe obesity in European adults referred for bariatric surgery. PloS ONE 8: e70735.
42. Malm-Erjefalt M. Bjornsdottir I. Vanggaard J. Helleberg H. Larsen U. Oosterhuis B. et al. (2010) Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 38: 1944–1953.
43. McCarthy M. (2010) Genomics, type 2 diabetes, and obesity. N Engl J Med 363: 2339–2350.
44. Nathan P. O'Neill B. Napolitano A. Bullmore E. (2011) Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther 17: 490–505.
45. O'Neil P. Smith S. Weissman N. Fidler M. Sanchez M. Zhang J. et al. (2012) Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 20: 1426–1436.
46. O'Rahilly S. Farooqi I. (2008) Human obesity: a heritable neurobehavioral disorder that is highly sensitive to environmental conditions. Diabetes 57: 2905–2910.
47. Paz-Filho G. Wong M. Licinio J. (2011) Ten years of leptin replacement therapy. Obes Rev 12: e315–e323.
48. Richard D. Ferland J. Lalonde J. Samson P. Deshaies Y. (2000) Influence of topiramate in the regulation of energy balance. Nutrition 16: 961–966.
49. Richelsen B. Tonstad S. Rossner S. Toubro S. Niskanen L. Madsbad S. et al. (2007) Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 30: 27–32.
50. Rodgers R. Tschop M. Wilding J. (2012) Anti-obesity drugs: past, present and future. Dis Model Mech 5: 621–626.
51. Ryan D. Bray G. (2013) Pharmacologic treatment options for obesity: what is old is new again. Curr Hypertens Rep 15: 182–189.
52. Saris W. (2001) Very-low-calorie diets and sustained weight loss. Obes Res 9(Suppl. 4): 295S-301S.
53. Shin J. Gadde K. (2013) Clinical utility of phentermine / topiramate (Qsymia) combination for the treatment of obesity. Diabetes Metab Syndr Obes 6: 131–139.
54. Sjostrom L. Narbro K. Sjostrom C. Karason K. Larsson B. Wedel H. et al. (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357: 741–752.
55. Sjostrom L. Peltonen M. Jacobson P. Sjostrom C. Karason K. Wedel H. et al. (2012) Bariatric surgery and long-term cardiovascular events. JAMA 307: 56–65.
56. Smith S. Weissman N. Anderson C. Sanchez M. Chuang E. Stubbe S. et al. (2010) Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 363: 245–256.
57. Sommer B. Mitchell E. Wroolie T. (2013) Topiramate: effects on cognition in patients with epilepsy, migraine headache and obesity. Ther Adv Neurol Disord 6: 211–227.
58. Speakman J. Levitsky D. Allison D. Bray M. de Castro J. Clegg D. et al. (2011) Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity. Dis Model Mech 4: 733–745.
59. Swinburn B. Sacks G. Hall K. McPherson K. Finegood D. Moodie M. et al. (2011) The global obesity pandemic: shaped by global drivers and local environments. Lancet 378: 804–814.
60. Unick J. Beavers D. Bond D. Clark J. Jakicic J. Kitabchi A. et al. (2013) The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med 126: 236–242, 242.e1–2.
61. Ussher J. Drucker D. (2012) Cardiovascular biology of the incretin system. Endocr Rev 33: 187–215.
62. Vilsboll T. Christensen M. Junker A. Knop F. Gluud L. (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344: d7771.
63. Wadden T. Hollander P. Klein S. Niswender K. Woo V. Hale P. et al. (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the scale maintenance randomized study. Int J Obes (Lond) 37: 1443-1451.
64. Wass J. Finer N. (2013) Action on obesity: comprehensive care for all. Clin Med 13: 4–5.
65. Wee C. Hamel M. Apovian C. Blackburn G. Bolcic-Jankovic D. Colten M. et al. (2013) Expectations for weight loss and willingness to accept risk among patients seeking weight loss surgery. JAMA Surg 148: 264–271.
66. Weissman N. Sanchez M. Koch G. Smith S. Shanahan W. Anderson C. (2013) Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging 6: 560–567.
67. Wheeler E. Huang N. Bochukova E. Keogh J. Lindsay S. Garg S. et al. (2013) Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity. Nat Genet 45: 513-517.
68. Whitlock G. Lewington S. Sherliker P. Clarke R. Emberson J. Halsey J. et al. (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373: 1083–1096.
69. Willer C. Speliotes E. Loos R. Li S. Lindgren C. Heid I. et al. (2009) Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 41: 25–34.
70. Wing R. Bolin P. Brancati F. Bray G. Clark J. Coday M. et al. (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369: 145–154.